Genovis bets on growing markets in Asia - continues expansion with new office in Hong Kong

Genovis bets on growing markets in Asia - continues expansion with new office in
Hong Kong

A number of Asian countries are making substantial investments in the life
sciences industry. Significant efforts first and foremost in stem cell research,
vaccine development and RNA interference have been carried out in recent years
in countries that include Singapore, South Korea and China. Core competency can
also be found in other large markets such as India, Japan and Australia. Genovis
is now establishing itself in the Asian market by opening an office in Hong
Kong. Genovis is a biotechnology company that develops and markets innovative
technologies for medical research. The company's shares are listed on the First
North part of OMX Nordic Exchange.

The Asian effort will be headed by Björn Hammarberg, who will represent Genovis
in the Asia-Pacific region and the Middle East. Björn Hammarberg has many years
of experience from molecular biology, including from KTH. He has also worked
with business development and the marketing of products and services to the
biotechnology industry and research institutes the world over on behalf of
companies such as AstraZeneca and PALL Life Sciences. 
“It is incredibly exciting to have the opportunity to participate early in the
commercialization phase and subsequently be a part of building the business in
the Asia-Pacific region and the Middle East,” says Björn Hammarberg, the Genovis
representative in Hong Kong. “Genovis technology, expertise and products are
quite timely with respect to the massive efforts that are being made in stem
cell research and RNAi in many quarters of the region.”


With the new office in Hong Kong and by hiring Björn Hammarberg Genovis is
gaining a platform from which to proceed for its business development and
marketing.


 “Obviously we wish to be competing in the markets that are making investments
and growing,” says Sarah Fredriksson, CEO of Genovis. “There is a strong drive
in this market and a large demand for new technologies and products, which I
hope that we will address and continue to develop. Initially, we will be
focusing primarily on Singapore, Japan and South Korea.” 


The market for Genovis products is growing annually by approx. 15-30 percent and
Asia is one of the markets that is showing the strongest growth. The Genovis
office in Hong Kong is yet another step in the company's expansion
internationally. Genovis will begin sales of its NIMT® technology for gene
transfer, magnetic labeling and siRNA delivery directly to customers on
September 27 of this year.



For additional information please contact:
Sarah Fredriksson,CEO
Genovis AB 
Tel: (+46) (0)46-101235
E-mail: Sarah.Fredriksson@genovis.com
www.genovis.com

Genovis is a biotechnology company with distinguished core competency in the
fields of nanotechnology and nanoparticles. The company's patented NIMT®
technology (NanoInducedMagneticTransfer) has been developed in order to enable
the life science industry to conduct effective preclinical research. Genovis
shares are listed on the First North stock exchange (OMX). Mangold
Fondkommission AB is a Certified Advisor and guarantor of liquidity to the
company.